Robert Balog

Robert Balog, Ph.D., leads Thermo Fisher Scientific’s Microarray R&D team, responsible for developing next-generation microarray hardware, software, and assay workflows to support the clinical and research genomics markets. Prior to his current role, he led the clinical system engineering team that was responsible for Thermo Fisher’s Amplitude High-Throughput SARS-CoV-2 testing platform. Dr. Balog has over 15 years of experience in product development from basic biomarker discovery to on market support of diagnostic testing systems in both genomics and proteomics. Prior to Thermo Fisher, he spent 3 years as CEO and co-founder of BioCeryx, developing automated microfluidic devices for noninvasive prenatal testing (NIPT), and over 13 years at SRI International, developing host response IVDs for radiation exposure and integrated nucleic acid analysis systems. Dr. Balog holds a Ph.D. in biomedical engineering from the University of Texas, Southwestern Medical Center, an MBA from the University of California, Berkeley and a B.E. in molecular biology and biomedical engineering from Vanderbilt University.